Superior Planning, LLC’s Summit Therapeutics SMMT Stock Holding History

Superior Planning, LLC’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.02K	Buy	+356	New	+$5.32K	﹤0.01%	1129

Other funds holding SMMT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Superior Planning, LLC's SMMT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 356 shares worth $6.02K. The stake represents ﹤0.01% of the portfolio and ranks #1129 among its holdings.

172 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Superior Planning, LLC held 356 shares of Summit Therapeutics worth $6.02K as of Q3 2026.
Summit Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Summit Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1129 holding.
172 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.